4/A: Maravai LifeSciences Director Equity Amendment
Form 4 Amendment
Director Gregory T. Lucier filed an amendment to correct the reported purchase price of restricted stock units granted on May 26, 2026.
Summary
- Gregory T. Lucier, a director at Maravai LifeSciences, received a grant of 46,293 restricted stock units (RSUs).
- The filing is an amendment to a previously submitted Form 4 to correct the reported price of the equity grant.
- The RSUs vest in full on the earlier of one year from the grant date or the 2027 annual meeting of stockholders.
- Following this transaction, the director holds 201,416 shares directly and 109,784 shares indirectly via a family partnership.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.
Positives
- Director alignment with shareholder interests through equity-based compensation.
Negatives
- Administrative error in the original filing necessitated an amendment.
Risks
- Standard market risks associated with equity ownership in the life sciences sector.
Future Outlook
The RSUs are scheduled to vest in full on the earlier of May 26, 2027, or the date of the 2027 annual meeting of stockholders.
Industry Context
StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to align board incentives with long-term company performance in the biotechnology and life sciences sector.
Comparison to Industry Standards
- The use of RSU grants for board compensation is consistent with standard practices for publicly traded life sciences companies.
- The vesting schedule of one year or the next annual meeting is a common retention and alignment mechanism.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation disclosure.
Next Steps
- Vesting of the 46,293 RSUs on the earlier of May 26, 2027, or the 2027 annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/26/2026 | Date of the RSU grant and earliest transaction. |
| 05/28/2026 | Date of the original filing and the amendment filing. |
Keywords
Maravai LifeSciences, MRVI, Director, Equity, Restricted Stock Units, SEC Filing, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.